摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonyl chloride | 169949-40-0

中文名称
——
中文别名
——
英文名称
3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonyl chloride
英文别名
3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonyl chloride;3-trifluoroacetyl-1,2,4,5-tetrahydro-3-benzazepine-7-sulfonyl chloride;3-trifluoroacetyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulphonyl chloride;3-trifluoroacetyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonyl chloride;3-(2,2,2-trifluoroacetyl)-1,2,4,5-tetrahydro-3-benzazepine-7-sulfonyl chloride
3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonyl chloride化学式
CAS
169949-40-0
化学式
C12H11ClF3NO3S
mdl
——
分子量
341.738
InChiKey
RUNLMHAGSMEMIA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    475.5±45.0 °C(Predicted)
  • 密度:
    1.489±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    21
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    62.8
  • 氢给体数:
    0
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(2,2,2-trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonyl chloride三乙胺 作用下, 以 四氢呋喃甲醇 为溶剂, 生成 N-[2-(4-benzyl-1-piperazinyl)ethyl]-2,3,4,5-tetrahydro-1H-3-benzazepine-7-sulfonamide
    参考文献:
    名称:
    EP1310490
    摘要:
    公开号:
  • 作为产物:
    参考文献:
    名称:
    [EN] 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS
    [FR] DERIVES DE 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE UTILISES COMME AGENTS ANTIPSYCHOTIQUES
    摘要:
    本发明提供式(I)的化合物:其中A和B分别表示基团-(CH2)m-和-(CH2)n-;R1表示氢或C1-6烷基;R2表示氢,卤素,羟基,氰基,硝基,羟基C1-6烷基,三氟甲基,三氟甲氧基,C1-6烷基,C1-6烷氧基,C1-6氟烷氧基,-(CH2)pC3-6环烷基,-(CH2)pOC3-6环烷基,-COC1-6烷基,-SO2C1-6烷基,-SOC1-6烷基,-S-C1-6烷基,-CO2C1-6烷基,-CO2NR5R6,-SO2NR5R6,-(CH2)pNR5R6,-(CH2)pNR5COR6,可选择取代的芳环,可选择取代的杂环或可选择取代的杂环基;R3表示氢,卤素,羟基,氰基,硝基,羟基C1-6烷基,三氟甲基,三氟甲氧基,C1-6烷基,C1-6烷氧基,C1-6氟烷氧基,-(CH2)pC3-6环烷基,-(CH2)pOC3-6环烷基,-COC1-6烷基,-SO2C1-6烷基,-SOC1-6烷基,-S-C1-6烷基,-CO2C1-6烷基,-CO2NR7R8,-SO2NR7R8,-(CH2)pNR7R8或-(CH2)pNR7COR8;R4表示氢,羟基,C1-6烷基,C1-6烷氧基,C1-6氟烷氧基,三氟甲基,三氟甲氧基,卤素,-OSO2CF3,-(CH2)pC3-6环烷基,-(CH2)qOC1-6烷基或-(CH2)pOC3-6环烷基;R5和R6各自独立地表示氢,C1-6烷基或与它们附着的氮或其他原子一起形成氮杂环烷基环或氧代取代的氮杂环烷基环;R7和R8各自独立地表示氢或C1-6烷基;m和n各自独立地表示选自1和2的整数;p独立地表示选自0,1,2和3的整数;q独立地表示选自1,2和3的整数;或其药学上可接受的盐或溶剂,但排除8-羟基-3-甲基-7-苯基磺酰基-2,3,4,5-四氢-1H-3-苯并噁唑,8-羟基-7-4-(羟基苯基)磺酰基-2,3,4,5-四氢-1H-3-苯并噁唑,7-苯基磺酰基-1,2,3,4-四氢异喹啉和7-苯基磺酰基-1,2,3,4-四氢异喹啉盐酸盐。该化合物在治疗中有用,特别是作为抗精神病药物。
    公开号:
    WO2003099792A1
点击查看最新优质反应信息

文献信息

  • [EN] ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES<br/>[FR] DERIVES ANTITHROMBOTIQUES D'AMIDINOPHENYLALANINE ET D'AMIDINOPYRIDYLALANINE
    申请人:PFIZER LIMITED
    公开号:WO1995013274A1
    公开(公告)日:1995-05-18
    (EN) Compounds of formula (I), pharmaceutically acceptable salt thereof, and pharmaceutically acceptable solvates of either entity, wherein X is CH or N; Y is optionally monounsaturated C3-C5 alkylene optionally substituted with C1-C4 alkyl or methylene; R1 is H; C1-C4 alkyl optionally substituted with C1-C4 alkoxy, OH, NR5R6, CONR5R6, C3-C6 cycloalkyl or aryl; or C3-C6 alkenyl; R2 is H; C1-C4 alkyl optionally substituted with C1-C4 alkoxy, OH, NR5R6, CONR5R6, C3-C6 cycloalkyl or aryl; or CONR5R6; R3 and R4 are each independently selected from H; C1-C4 alkyl optionally substituted with NR5R6; C1-C4 alkoxy; halo; CONR5R6 and aryl; R5 and R6 are each independently selected from H and C1-C4 alkyl; and m and n are each independently 1, 2 or 3; are potent and selective thrombin inhibitors useful in the treatment of, inter alia, deep vein thrombosis; reocclusion following thrombolytic therapy; chronic arterial obstruction; peripheral vascular disease; acute myocardial infarction; unstable angina; atrial fibrillation; thrombotic stroke; transient ischaemic attacks; restenosis and occlusion following angioplasty; or neurodegenerative disorders.(FR) Composés répondant à la formule (I), leur sel pharmaceutiquement acceptable, et les solvates pharmaceutiquement acceptables de l'une ou l'autre de ces entités. Dans ladite formule, X représente CH ou N; Y représente alkylène C3-5 éventuellement monoinsaturé éventuellement substitué par alkyle C1-4 ou méthylène; R1 représente H, alkyle C1-4 éventuellement substitué par alcoxy C1-4, OH, NR5R6, CONR5R6, cycloalkyle C3-6 ou aryle, ou alcényle C3-6; R2 représente H, alkyle C1-4 éventuellement substitué par alcoxy C1-4, OH, NR5R6, CONR5R6, cycloalkyle C3-6 ou aryle, ou CONR5R6; R3 et R4, indépendamment l'un de l'autre, représentent H, alkyle C1-4 éventuellement substitué par NR5R6, alcoxy C1-4, halo, CONR5R6 ou aryle; R5 et R6, indépendamment l'un de l'autre, représentent H ou alkyle C1-4; et m et n, indépendamment l'un de l'autre, valent 1, 2 ou 3. Ces composés sont des inhibiteurs puissants et sélectifs de la thrombine utilisables dans le traitement, entre autres, de la thrombose veineuse profonde, de la réocclusion suivant un traitement thrombolytique, de l'obstruction artérielle chronique, des maladies vasculaires périphériques, de l'infarctus du myocarde aigu, de l'angor instable, de la fibrillation auriculaire, des accès thrombotiques, des accidents ischémiques transitoires, de la resténose et de l'occlusion suivant l'angioplastie, ou des troubles neurodégénératifs.
    (I)式化合物、其药学上可接受的盐和任一实体的药学上可接受的溶剂,其中X为CH或N; Y为可选的单不饱和C3-C5烷基,可选地取代C1-C4烷基或亚甲基; R1为H; C1-C4烷基,可选地取代C1-C4烷氧基、OH、NR5R6、CONR5R6、C3-C6环烷基或芳基; 或C3-C6烯基; R2为H; C1-C4烷基,可选地取代C1-C4烷氧基、OH、NR5R6、CONR5R6、C3-C6环烷基或芳基; 或CONR5R6; R3和R4各自独立地选自H; C1-C4烷基,可选地取代NR5R6; C1-C4烷氧基; 卤素; CONR5R6和芳基; R5和R6各自独立地选自H和C1-C4烷基; m和n各自独立地为1、2或3; 是有效且选择性的凝血酶抑制剂,用于治疗深静脉血栓形成,溶栓治疗后的再闭塞,慢性动脉阻塞,周围血管疾病,急性心肌梗死,不稳定性心绞痛,心房颤动,血栓性中风,短暂性脑缺血发作,血管成形术后的再狭窄和闭塞,或神经退行性疾病的治疗中。
  • 7-Phenylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents
    申请人:Forbes Thomson Ian
    公开号:US20050245507A1
    公开(公告)日:2005-11-03
    The invention provides compounds of formula (I): wherein A and B represent the groups —(CH 2 ) m — and —(CH 2 ) n — respectively; R 1 represents hydrogen or C 1-6 alkyl; R 2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC 1-6 alkyl, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy, —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) p OC 3-6 cycloalkyl, —COC 1-6 alkyl, —SO 2 C 1-6 alkyl, —SOC 1-6 alkyl, —S—C 1-6 alkyl, —CO 2 C 1-6 alkyl, —CO 2 NR 5 R 6 , —SO 2 NR 5 R 6 , —(CH 2 ) p NR 5 R 6 , —(CH 2 ) p NR 5 COR 6 , optionally substituted aryl ring, optionally substituted heteroaryl ring or optionally substituted heterocyclyl ring; R 3 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC 1-6 alkyl, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy, —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) p OC 3-6 cycloalkyl, —COC 1-6 alkyl, —SO 2 C 1-6 alkyl, —SOC 1-6 alkyl, —S—C 1-6 alkyl, —CO 2 C 1-6 alkyl, —CO 2 NR 7 R 8 , —SO 2 NR 7 R 8 , —(CH 2 ) p NR 7 R 8 or —(CH 2 ) p NR 7 COR 8 ; R 4 represents hydrogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy, trifluoromethyl, trifluoromethoxy, halogen, —OSO 2 CF 3 , —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) q OC 1-6 alkyl or —(CH 2 ) p OC 3-6 cycloalkyl; R 5 and R 6 each independently represent hydrogen, C 1-6 alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring; R 7 and R 8 each independently represent hydrogen or C 1-6 alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; q independently represents an integer selected from 1, 2 and 3; or a pharmaceutically acceptable salt or solvate thereof, with the proviso that the compounds 8-hydroxy-3-methyl-7-phenylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 8-hydroxy-7-4-(hydroxyphenyl)sulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline and 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline hydrochloride are excluded. The compounds are useful in therapy, in particular as antipsychotic agents.
    该发明提供了式(I)的化合物: 其中,A和B分别表示基团—(CH2)m—和—( )n—; R1表示氢或C1-6烷基; R2表示氢、卤素、羟基、基、硝基、羟基C1-6烷基、三甲基、三甲氧基、C1-6烷基、C1-6烷氧基、C1-6氟烷氧基、—( )pC3-6环烷基、—( )pOC3-6环烷基、—COC1-6烷基、—SO2C1-6烷基、—SOC1-6烷基、—S—C1-6烷基、—CO2C1-6烷基、—CO2NR5R6、—SO2NR5R6、—( )pNR5R6、—( )pNR5COR6、可选择的取代芳环、可选择的取代杂芳环或可选择的取代杂环基; R3表示氢、卤素、羟基、基、硝基、羟基C1-6烷基、三甲基、三甲氧基、C1-6烷基、C1-6烷氧基、C1-6氟烷氧基、—( )pC3-6环烷基、—( )pOC3-6环烷基、—COC1-6烷基、—SO2C1-6烷基、—SOC1-6烷基、—S—C1-6烷基、—CO2C1-6烷基、—CO2NR7R8、—SO2NR7R8、—( )pNR7R8或—( )pNR7COR8; R4表示氢、羟基、C1-6烷基、C1-6烷氧基、C1-6氟烷氧基、三甲基、三甲氧基、卤素、—OSO2CF3、—( )pC3-6环烷基、—( )qOC1-6烷基或—( )pOC3-6环烷基; R5和R6分别独立地表示氢、C1-6烷基或与它们连接的氮或其他原子一起形成氮杂环烷基或氧代取代的氮杂环烷基环; R7和R8分别独立地表示氢或C1-6烷基; m和n分别独立地表示选自1和2的整数; p独立地表示选自0、1、2和3的整数; q独立地表示选自1、2和3的整数; 或其药学上可接受的盐或溶剂,但排除8-羟基-3-甲基-7-苯基磺酰基-2,3,4,5-四氢-1H-3-苯并哌嗪、8-羟基-7-4-(羟基苯基)磺酰基-2,3,4,5-四氢-1H-3-苯并哌嗪、7-苯基磺酰基-1,2,3,4-四氢异喹啉和7-苯基磺酰基-1,2,3,4-四氢异喹啉盐酸盐化合物。该化合物在治疗中有用,特别是作为抗精神病药物。
  • Compounds
    申请人:Forbes Thomson Ian
    公开号:US20050261279A1
    公开(公告)日:2005-11-24
    The invention provides compounds of formula (I): wherein A and B represent the groups —(CH 2 ) m — and —(CH 2 ) n — respectively; R 1 represents hydrogen or C 1-6 alkyl; R 2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxy C 1-6 alkyl, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy, —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) p OC 3-6 cycloalkyl, —COC 1-6 alkyl, —SO 2 C 1-6 alkyl, —SOC 1-6 alkyl, —S—C 1-6 alkyl, —CO 2 C 1-6 alkyl, —CO 2 NR 5 R 6 , —SO 2 NR 5 R 6 , —(CH 2 ) p NR 5 R 6 , —(CF) p NR 5 COR 6 , optionally substituted aryl ring, optionally substituted heteroaryl ring or optionally substituted heterocyclyl ring; R 3 represents optionally substituted aryl ring or optionally substituted heteroaryl ring; R 4 represents hydrogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, trifluoromethyl, trifluoromethoxy, halogen, —OSO 2 CF 3 , —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) q OC 1-6 alkyl or —(CH 2 ) p OC 3-6 cycloalkyl; R 5 and R 6 each independently represent hydrogen, C 1-6 alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring; Z represents —(CH 2 ) r X— wherein the —(CH 2 ) r — group is attached to R 3 , or —X(CH 2 ) r — wherein X is attached to R 3 , and wherein any of the —CH 2 — groups may be optionally substituted by one or more C 1-6 alkyl groups; X represents oxygen, —NR 7 or —CH 2 — wherein the —CH 2 — group may be optionally substituted by one or more C 1-6 alkyl groups; R 7 represents hydrogen or C 1-6 alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; q independently represents an integer selected from 1, 2 and 3; r independently represents an integer selected from 0, 1, and 2; or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful in therapy, in particular as antipsychotic agents.
    本发明提供了式(I)的化合物: 其中,A和B分别代表基团—(CH2)m—和—( )n—;R1代表氢或C1-6烷基;R2代表氢、卤素、羟基、基、硝基、羟基C1-6烷基、三甲基、三甲氧基、C1-6烷基、C1-6烷氧基、C1-6氟烷氧基、—( )pC3-6环烷基、—( )pOC3-6环烷基、—COC1-6烷基、—SO2C1-6烷基、—SOC1-6烷基、—S—C1-6烷基、—CO2C1-6烷基、—CO2NR5R6、—SO2NR5R6、—( )pNR5R6、—(CF)pNR5COR6、可选地取代的芳环、可选地取代的杂芳环或可选地取代的杂环基;R3代表可选地取代的芳环或可选地取代的杂芳环;R4代表氢、羟基、C1-6烷基、C1-6烷氧基、三甲基、三甲氧基、卤素、—OSO2CF3、—( )pC3-6环烷基、—( )qOC1-6烷基或—( )pOC3-6环烷基;R5和R6各自独立地代表氢、C1-6烷基或与它们所连接的氮或其他原子一起形成氮杂环烷基或氧代取代的氮杂环烷基;Z代表—( )rX—,其中—( )r—基团连接到R3,或—X( )r—,其中X连接到R3,其中任何一个— —基团可以可选地被一个或多个C1-6烷基基团取代;X代表氧、—NR7或— —,其中— —基团可以可选地被一个或多个C1-6烷基基团取代;R7代表氢或C1-6烷基;m和n独立地代表选自1和2的整数;p独立地代表选自0、1、2和3的整数;q独立地代表选自1、2和3的整数;r独立地代表选自0、1和2的整数;或其药学上可接受的盐或溶剂。这些化合物在治疗中有用,特别是作为抗精神病药物。
  • 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders
    申请人:Ahmed Mahmood
    公开号:US20050176759A1
    公开(公告)日:2005-08-11
    Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
    发明了非肽类TPO模拟剂。还发明了一种治疗血小板减少症的方法,包括在需要的哺乳动物,包括人类中,向这种哺乳动物施用所选羟基-1-偶氮苯生物的有效量。
  • Gpr14 antagonist
    申请人:——
    公开号:US20040063699A1
    公开(公告)日:2004-04-01
    A novel GPR14 antagonist. The GPR14 antagonist comprises a compound represented by the formula (I) or a salt thereof wherein Ar represents optionally substituted aryl; X represents a spacer; n is an integer of 1 to 10; R represents an optionally substituted hydrocarbon group, etc., provided that R may be bonded to Ar, etc. to form a ring; and Y represents optionally substituted amino, etc. 1
    一种新型的GPR14拮抗剂。该GPR14拮抗剂包括由式(I)或其盐所表示的化合物,其中Ar代表可选取代的芳基; X代表一个间隔物; n为1到10的整数; R代表可选取代的碳氢基团等,但R可以与Ar等连接形成环; Y代表可选取代的基等。
查看更多